Avianax

Avianax is a biotechnology company specializing in the development of high-affinity, avian-derived polyclonal antibodies to treat infectious diseases and various forms of cancer. The company utilizes a proprietary platform that leverages the unique immune system of geese to produce therapeutic antibodies (IgY), which are then purified for human administration. Their lead program, a treatment for West Nile Virus, has progressed into Phase 1/2 clinical trials, demonstrating the platform's potential for rapid response to emerging viral threats. Avianax aims to provide cost-effective and scalable immunotherapy solutions for global health challenges including Rabies, Ebola, and Zika.